BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 29040161)

  • 1. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
    Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
    Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
    Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
    Hu RT; Liu DS; Li B
    BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.
    Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A
    Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
    Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid volume is the key predictor of hyperthyroidism remission after radioactive iodine therapy in pediatric patients.
    Sheremeta M; Korchagina M; Trukhin A; Nagaeva E; Bezlepkina O; Peterkova V
    Eur J Pediatr; 2023 Nov; 182(11):4931-4937. PubMed ID: 37606704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
    Zheng W; Jian T; Guizhi Z; Zhaowei M; Renfei W
    Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease.
    Santos RB; Romaldini JH; Ward LS
    Thyroid; 2004 Jul; 14(7):525-30. PubMed ID: 15307942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
    Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
    Chen DY; Chen TH
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing the success of radioiodine therapy in patients with Graves' disease.
    Šfiligoj D; Gaberšček S; Mekjavič PJ; Pirnat E; Zaletel K
    Nucl Med Commun; 2015 Jun; 36(6):560-5. PubMed ID: 25714667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism?
    Vijayakumar V; Ali S; Nishino T; Nusynowitz M
    Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V; Voth E; Moka D; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
    Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
    Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves' disease patients.
    Zhang R; Tan J; Wang R; Zhang G; Jia Q; Meng Z; Zhang Y
    Sci Rep; 2017 Aug; 7(1):8301. PubMed ID: 28811561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
    Körber C; Schneider P; Körber-Hafner N; Hänscheid H; Reiners C
    Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
    Ruchała M; Sowiński J; Dolata M; Junik R; Gembicki M; Skiba A
    Nucl Med Rev Cent East Eur; 2005; 8(1):28-32. PubMed ID: 15977144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.